seed
Stage
1
Investors
About
Replay develops technologies to deliver very large DNA payloads to a range of cell types, including a high-capacity HSV vector for gene delivery and a hypoimmunogenic iPSC therapeutic platform. The company’s work is focused on enabling cell and gene therapies by improving payload capacity and reducing immune rejection.
Explore Replay's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.